Detalles de la búsqueda
1.
Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study.
Mod Rheumatol;
33(1): 122-133, 2023 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34915574
2.
Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses.
Mod Rheumatol;
33(4): 751-757, 2023 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36208293
3.
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.
RMD Open;
8(1)2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35428697
4.
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.
RMD Open;
7(2)2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34215703
Resultados
1 -
4
de 4
1
Próxima >
>>